Covered recipient · General Payments record
EDWARD L LAIN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$515,869.38
535 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $326,671.28 | 103 |
| Consulting Fee | $74,107.50 | 17 |
| Travel and Lodging | $39,224.37 | 104 |
| Grant | $33,750.00 | 2 |
| Compensation for serving as faculty or as a speaker for a medical education program | $25,900.00 | 6 |
| Food and Beverage | $11,640.07 | 299 |
| Education | $4,576.16 | 4 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Galderma Laboratories, L.P. | $90,256.34 | 112 |
| E.R. Squibb & Sons, L.L.C. | $78,503.59 | 43 |
| PFIZER INC. | $67,356.73 | 56 |
| Dermavant Sciences, Inc. | $46,691.95 | 35 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $41,842.19 | 44 |
| ABBVIE INC. | $37,284.87 | 29 |
| Arcutis Biotherapeutics, Inc. | $32,306.48 | 46 |
| Incyte Corporation | $32,079.97 | 33 |
| Lilly USA, LLC | $20,347.08 | 21 |
| Regeneron Healthcare Solutions, Inc. | $17,843.21 | 30 |
| Almirall LLC | $15,429.26 | 12 |
| GENZYME CORPORATION | $13,977.43 | 19 |
| UCB, Inc. | $10,217.51 | 15 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $4,811.00 | 13 |
| Janssen Global Services, LLC | $3,020.25 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,169.38 | 10 |
| Biofrontera Inc. | $1,383.18 | 3 |
| LEO Pharma Inc. | $181.73 | 2 |
| Janssen Biotech, Inc. | $45.37 | 2 |
| STRATA Skin Sciences, Inc. | $45.31 | 3 |
| Amgen Inc. | $32.27 | 1 |
| Biofrontera Bioscience GmbH | $22.84 | 2 |
| Organon LLC | $21.44 | 1 |
Page 3 of 11; records 101–150 of 535 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EDWARD L LAIN
NPI 1124079306 · CMS profile ID 6301
Allopathic & Osteopathic Physicians / Dermatology
AUSTIN, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 11; records 101–150 of 535 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1124079306?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EDWARD L LAIN, NPI 1124079306, CMS profile ID 6301. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 11; records 101–150 of 535 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124079306?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). EDWARD L LAIN, NPI 1124079306, CMS profile ID 6301. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 11; records 101–150 of 535 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124079306?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- EDWARD L LAIN, NPI 1124079306, CMS profile ID 6301, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 11; records 101–150 of 535 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124079306?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
535 matching records · $515,869.38 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 535.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Ortho Dermatologics, a division of Bausch Health US, LLC | $732.80 | 11/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051606943 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $16.68 | 11/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051606947 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $704.87 | 11/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051606953 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $136.88 | 11/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051606963 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $83.00 | 11/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051606977 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $682.72 | 11/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051606983 | CMS |
| Arcutis Biotherapeutics, Inc. | $1,875.00 | 11/01/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044699333 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.98 | 11/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015808027 | CMS |
| PFIZER INC. | $700.00 | 11/01/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050658609 | CMS |
| Sun Pharmaceutical Industries Inc. | $9.14 | 10/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053840169 | CMS |
| Dermavant Sciences, Inc. | $1,600.00 | 10/26/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991214907 | CMS |
| Arcutis Biotherapeutics, Inc. | $19.10 | 10/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044699543 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,572.50 | 10/24/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015808017 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $1,400.00 | 10/24/2023 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051607067 | CMS |
| PFIZER INC. | $4,500.00 | 10/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050489419 | CMS |
| ABBVIE INC. | $89.85 | 10/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997717167 | CMS |
| Galderma Laboratories, L.P. | $15.45 | 10/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059709741 | CMS |
| Regeneron Healthcare Solutions, Inc. | $32.65 | 10/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999263809 | CMS |
| GENZYME CORPORATION | $54.83 | 10/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049981207 | CMS |
| GENZYME CORPORATION | $28.02 | 10/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049981211 | CMS |
| GENZYME CORPORATION | $3,170.00 | 10/20/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049981215 | CMS |
| PFIZER INC. | $143.50 | 10/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050691683 | CMS |
| Arcutis Biotherapeutics, Inc. | $75.05 | 10/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044699321 | CMS |
| Biofrontera Inc. | $80.53 | 10/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059548543 | CMS |
| Galderma Laboratories, L.P. | $58.68 | 10/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059709737 | CMS |
| Incyte Corporation | $24.55 | 10/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044183335 | CMS |
| PFIZER INC. | $124.06 | 10/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050649529 | CMS |
| Regeneron Healthcare Solutions, Inc. | $452.00 | 10/19/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999263805 | CMS |
| Biofrontera Inc. | $24.01 | 10/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017335099 | CMS |
| Incyte Corporation | $22.01 | 10/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044183309 | CMS |
| UCB, Inc. | $19.95 | 10/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021440915 | CMS |
| ABBVIE INC. | $31.12 | 10/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997717165 | CMS |
| GENZYME CORPORATION | $28.40 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049981175 | CMS |
| Galderma Laboratories, L.P. | $19.23 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059709729 | CMS |
| Galderma Laboratories, L.P. | $4.66 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059709731 | CMS |
| Galderma Laboratories, L.P. | $5.22 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059709735 | CMS |
| Regeneron Healthcare Solutions, Inc. | $24.63 | 10/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999263795 | CMS |
| Regeneron Healthcare Solutions, Inc. | $40.00 | 10/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999263799 | CMS |
| Regeneron Healthcare Solutions, Inc. | $272.06 | 10/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999263801 | CMS |
| PFIZER INC. | $4,800.00 | 10/09/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050681069 | CMS |
| Sun Pharmaceutical Industries Inc. | $9.72 | 10/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053840173 | CMS |
| PFIZER INC. | $672.84 | 10/07/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050428101 | CMS |
| PFIZER INC. | $460.69 | 10/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049583087 | CMS |
| PFIZER INC. | $667.80 | 10/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049583091 | CMS |
| PFIZER INC. | $392.47 | 10/06/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049583297 | CMS |
| ABBVIE INC. | $22.19 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997717163 | CMS |
| PFIZER INC. | $106.00 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050610471 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5.69 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999263791 | CMS |
| UCB, Inc. | $45.36 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021440927 | CMS |
| UCB, Inc. | $104.20 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021440929 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $27,129.42 | 6 |
| PY2025 | Principal investigator | $1,018,334.09 | 168 |
| PY2024 | Recipient | $83,492.49 | 4 |
| PY2024 | Principal investigator | $812,640.42 | 213 |
| PY2023 | Principal investigator | $847,983.34 | 225 |
| PY2022 | Recipient | $3,095.32 | 11 |
| PY2022 | Principal investigator | $2,197,912.59 | 171 |
| PY2021 | Recipient | $3,481.87 | 1 |
| PY2021 | Principal investigator | $1,457,384.75 | 112 |
| PY2020 | Recipient | $13,272.52 | 11 |
| PY2020 | Principal investigator | $1,246,211.91 | 128 |
| PY2019 | Recipient | $74,533.35 | 60 |
| PY2019 | Principal investigator | $1,861,865.07 | 102 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
174 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $916.68 | 12/31/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202534987 |
| Principal investigator 1 | ABBVIE INC. | $32,612.93 | 12/31/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation | No dispute reported | 06/30/2026 | 1202534989 |
| Principal investigator 1 | ABBVIE INC. | $2,177.82 | 12/31/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX in Subjects for Treatment of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202534991 |
| Principal investigator 1 | Biofrontera Inc. | $17,013.50 | 12/22/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY | No dispute reported | 06/30/2026 | 1208907819 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,427.00 | 12/22/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area | No dispute reported | 06/30/2026 | 1175375367 |
| Principal investigator 1 | ABBVIE INC. | $4,388.40 | 12/17/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202531018 |
| Principal investigator 1 | ABBVIE INC. | $400.00 | 12/11/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202530228 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $6,040.00 | 12/10/2025 | Non-covered Recipient Entity PFLUGERVILLE DERM CLIN REA CEN | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232947188 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 12/05/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504173 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 12/05/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504177 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 12/05/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504195 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 12/05/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504198 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504170 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504181 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 12/01/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504191 |
| Principal investigator 1 | Biofrontera Inc. | $13,967.50 | 11/27/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY | No dispute reported | 06/30/2026 | 1208907753 |
| Principal investigator 1 | Biofrontera Inc. | $12,818.85 | 11/27/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY | No dispute reported | 06/30/2026 | 1208907757 |
| Principal investigator 1 | Eli Lilly and Company | $4,903.00 | 11/25/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187877129 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $310.50 | 11/19/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430892 |
| Principal investigator 1 | ABBVIE INC. | $2,701.20 | 11/13/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202524069 |
| Principal investigator 1 | ABBVIE INC. | $36,533.60 | 11/13/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202524071 |
| Principal investigator 1 | Incyte Corporation | $2,321.65 | 11/06/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo | No dispute reported | 06/30/2026 | 1240504165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,262.00 | 11/03/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375274 |
| Recipient | Nielsen BioSciences, Inc. | $26,518.41 | 10/30/2025 | Covered Recipient Physician | CFW-3A | No dispute reported | 06/30/2026 | 1223438117 |
| Principal investigator 1 | PFIZER INC. | $2,214.00 | 10/29/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228742094 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $100.00 | 10/28/2025 | Non-covered Recipient Entity PFLUGERVILLE DERM CLIN REA CEN | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946790 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,730.00 | 10/28/2025 | Non-covered Recipient Entity PFLUGERVILLE DERM CLIN REA CEN | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946794 |
| Principal investigator 1 | Biofrontera Inc. | $583.25 | 10/24/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907714 |
| Principal investigator 1 | Biofrontera Inc. | $665.13 | 10/24/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907716 |
| Principal investigator 1 | Incyte Corporation | $245.30 | 10/22/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240504201 |
| Principal investigator 1 | ABBVIE INC. | $36,117.00 | 10/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202517213 |
| Principal investigator 1 | ABBVIE INC. | $2,701.20 | 10/15/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202516913 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,085.00 | 10/15/2025 | Non-covered Recipient Entity PFLUGERVILLE DERM CLIN REA CEN | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946586 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $7,000.00 | 10/15/2025 | Non-covered Recipient Entity PFLUGERVILLE DERM CLIN REA CEN | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946589 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,328.75 | 10/10/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430890 |
| Principal investigator 1 | Incyte Corporation | $2,049.00 | 10/08/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504185 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,050.23 | 10/08/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL RESEARCH CENTER INC | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190307313 |
| Recipient | ABBVIE INC. | $53.69 | 10/04/2025 | Covered Recipient Physician | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars | No dispute reported | 06/30/2026 | 1202399508 |
| Recipient | ABBVIE INC. | $21.48 | 10/04/2025 | Covered Recipient Physician | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars | No dispute reported | 06/30/2026 | 1202399512 |
| Recipient | ABBVIE INC. | $125.35 | 10/03/2025 | Covered Recipient Physician | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars | No dispute reported | 06/30/2026 | 1202399497 |
| Recipient | ABBVIE INC. | $123.49 | 10/03/2025 | Covered Recipient Physician | A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars | No dispute reported | 06/30/2026 | 1202399501 |
| Recipient | ABBVIE INC. | $287.00 | 10/03/2025 | Covered Recipient Physician | A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars | No dispute reported | 06/30/2026 | 1202399504 |
| Principal investigator 1 | PFIZER INC. | $1,295.33 | 09/26/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228769832 |
| Principal investigator 1 | PFIZER INC. | $14,858.85 | 09/24/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228758485 |
| Principal investigator 1 | ABBVIE INC. | $31,729.65 | 09/19/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202511656 |
| Principal investigator 1 | PFIZER INC. | $2,214.00 | 09/19/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228757967 |
| Principal investigator 1 | ABBVIE INC. | $2,701.20 | 09/18/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202511482 |
| Principal investigator 1 | ABBVIE INC. | $500.40 | 09/17/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202511198 |
| Principal investigator 1 | PFIZER INC. | $2,094.53 | 09/12/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228770454 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $9,305.00 | 09/12/2025 | Non-covered Recipient Entity PFLUGERVILLE DERM CLIN REA CEN | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946378 |
| Principal investigator 1 | Incyte Corporation | $1,425.00 | 09/10/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504132 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 09/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504093 |
| Principal investigator 1 | Incyte Corporation | $86.00 | 09/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504156 |
| Principal investigator 1 | PFIZER INC. | $444.90 | 08/23/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228768057 |
| Principal investigator 1 | ABBVIE INC. | $12,492.00 | 08/14/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202504913 |
| Principal investigator 1 | ABBVIE INC. | $96,875.25 | 08/14/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202504915 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504105 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504113 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504117 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504121 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504125 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504129 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504137 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504141 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504144 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504149 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504151 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 08/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 08/04/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175283691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,683.00 | 08/04/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175375360 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,913.00 | 08/01/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375347 |
| Principal investigator 1 | ABBVIE INC. | $74.40 | 07/29/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202500326 |
| Principal investigator 1 | PFIZER INC. | $2,299.73 | 07/29/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228764041 |
| Principal investigator 1 | ABBVIE INC. | $62.38 | 07/18/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202498908 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 07/18/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504097 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 07/18/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504109 |
| Principal investigator 1 | ABBVIE INC. | $226,893.60 | 07/17/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202498594 |
| Principal investigator 1 | PFIZER INC. | $1,136.03 | 07/17/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228785865 |
| Principal investigator 1 | ABBVIE INC. | $13,842.60 | 07/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202498378 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,328.75 | 07/15/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430884 |
| Principal investigator 1 | Incyte Corporation | $1,425.00 | 07/09/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504101 |
| Principal investigator 1 | Biofrontera Inc. | $77.28 | 07/07/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY | No dispute reported | 06/30/2026 | 1208907538 |
| Principal investigator 1 | ABBVIE INC. | $537.60 | 07/02/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202494905 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 07/01/2025 | Covered Recipient Teaching Hospital Mayo Clinic Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240476508 |
| Principal investigator 1 | Incyte Corporation | $24.30 | 07/01/2025 | Covered Recipient Teaching Hospital Mayo Clinic Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240476513 |
| Principal investigator 1 | Biofrontera Inc. | $8.40 | 06/25/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). | No dispute reported | 06/30/2026 | 1208907501 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,000.00 | 06/24/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430862 |
| Principal investigator 1 | ABBVIE INC. | $49,551.75 | 06/17/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) | No dispute reported | 06/30/2026 | 1202491853 |
| Principal investigator 1 | ABBVIE INC. | $15,376.80 | 06/12/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202491317 |
| Principal investigator 1 | Incyte Corporation | $1,425.00 | 06/11/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504054 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,427.00 | 06/09/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175375300 |
| Principal investigator 1 | Eli Lilly and Company | $901.25 | 06/05/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187875279 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 06/03/2025 | Covered Recipient Teaching Hospital Mayo Clinic Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240476495 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 06/03/2025 | Covered Recipient Teaching Hospital Mayo Clinic Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240476501 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 06/03/2025 | Covered Recipient Teaching Hospital Mayo Clinic Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240476505 |
| Principal investigator 1 | Janssen Research & Development, LLC | $79.73 | 05/30/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375354 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,714.00 | 05/26/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375321 |
| Principal investigator 1 | ABBVIE INC. | $889.20 | 05/22/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202485953 |
| Principal investigator 1 | ABBVIE INC. | $20,942.40 | 05/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202485369 |
| Principal investigator 1 | PFIZER INC. | $1,059.08 | 05/16/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228764368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $79.73 | 05/01/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375286 |
| Principal investigator 1 | Janssen Research & Development, LLC | $527.46 | 05/01/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375315 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 05/01/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375338 |
| Principal investigator 1 | ABBVIE INC. | $2,274.00 | 04/24/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage | No dispute reported | 06/30/2026 | 1202478955 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 04/23/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504034 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 04/23/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504038 |
| Principal investigator 1 | ABBVIE INC. | $15,346.20 | 04/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202476905 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,500.00 | 04/14/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226087113 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $500.00 | 04/11/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines | No dispute reported | 06/30/2026 | 1234514147 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,025.00 | 04/11/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430876 |
| Principal investigator 1 | Incyte Corporation | $1,425.00 | 04/09/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504030 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 04/09/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504046 |
| Principal investigator 1 | Incyte Corporation | $75.00 | 04/09/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504050 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 04/09/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504074 |
| Principal investigator 1 | PFIZER INC. | $1,519.43 | 04/09/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228778757 |
| Principal investigator 1 | Janssen Research & Development, LLC | $439.19 | 04/07/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375265 |
| Principal investigator 1 | ABBVIE INC. | $960.30 | 04/03/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage | No dispute reported | 06/30/2026 | 1202470545 |
| Principal investigator 1 | Biofrontera Inc. | $1,982.97 | 04/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907409 |
| Principal investigator 1 | Biofrontera Inc. | $1,702.56 | 04/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907412 |
| Principal investigator 1 | Biofrontera Inc. | $2,384.50 | 04/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907417 |
| Principal investigator 1 | Biofrontera Inc. | $1,770.00 | 04/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907422 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504042 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504058 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504062 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504066 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504070 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504078 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504083 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504085 |
| Principal investigator 1 | Incyte Corporation | $5.38 | 04/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504088 |
| Principal investigator 1 | ABBVIE INC. | $426.00 | 03/26/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202466247 |
| Principal investigator 1 | Eli Lilly and Company | $1,084.80 | 03/25/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187874823 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,459.00 | 03/21/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375308 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $209.25 | 03/21/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430874 |
| Principal investigator 1 | ABBVIE INC. | $47,295.45 | 03/20/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY | A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage | No dispute reported | 06/30/2026 | 1202464922 |
| Principal investigator 1 | ABBVIE INC. | $47,295.45 | 03/20/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | C24-AD101 - A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage | No dispute reported | 06/30/2026 | 1202465227 |
| Principal investigator 1 | ABBVIE INC. | $852.00 | 03/14/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202463885 |
| Principal investigator 1 | ABBVIE INC. | $16,764.00 | 03/13/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202463576 |
| Principal investigator 1 | Incyte Corporation | $1,569.00 | 03/12/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503978 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,995.00 | 03/06/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175375293 |
| Principal investigator 1 | PFIZER INC. | $4,326.09 | 03/04/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228719525 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 03/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503996 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 03/03/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504001 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,105.18 | 03/03/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175283707 |
| Principal investigator 1 | Biofrontera Inc. | $1,500.00 | 02/28/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | A NON-RANODMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BF-200 ALA (AMELUZ) AND BF-RHODOLED XL IN THE EXPANDED FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS ON THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY (PDT) | No dispute reported | 06/30/2026 | 1208907370 |
| Principal investigator 1 | Amgen Inc. | $2,750.00 | 02/22/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH | A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis | No dispute reported | 06/30/2026 | 1246639487 |
| Principal investigator 1 | Eli Lilly and Company | $6,094.00 | 02/18/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187880871 |
| Principal investigator 1 | ABBVIE INC. | $26,796.60 | 02/13/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202451409 |
| Principal investigator 1 | PFIZER INC. | $5,890.88 | 02/11/2025 | Non-covered Recipient Entity Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228748957 |
| Principal investigator 1 | Incyte Corporation | $172.00 | 02/07/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503965 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 02/07/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503968 |
| Principal investigator 1 | Incyte Corporation | $75.00 | 02/07/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504021 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,051.00 | 02/07/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175375331 |
| Principal investigator 1 | Almirall LLC | $50.00 | 02/05/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc. | Tirbanibulin in superficial BCC (sBCC). Interventional, 2 arms, prospective study | No dispute reported | 06/30/2026 | 1243871668 |
| Principal investigator 1 | Janssen Research & Development, LLC | $224.36 | 02/05/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175283668 |
| Principal investigator 1 | Eli Lilly and Company | $2,302.00 | 02/04/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187875531 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,025.00 | 02/04/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430866 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20,373.88 | 02/01/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL RESEARCH CENTER INC | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190307503 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 01/24/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504013 |
| Principal investigator 1 | Almirall LLC | $69.00 | 01/22/2025 | Non-covered Recipient Entity Austin Institute for Clinical Research, Inc. | Tirbanibulin in superficial BCC (sBCC). Interventional, 2 arms, prospective study | No dispute reported | 06/30/2026 | 1243871670 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,105.18 | 01/20/2025 | Non-covered Recipient Entity Austin Inst For Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175283662 |
| Principal investigator 1 | ABBVIE INC. | $30,514.80 | 01/16/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202439429 |
| Principal investigator 1 | Biofrontera Inc. | $6,655.11 | 01/15/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907270 |
| Principal investigator 1 | Incyte Corporation | $1,557.00 | 01/15/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503961 |
| Principal investigator 1 | Incyte Corporation | $1,517.00 | 01/15/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503973 |
| Principal investigator 1 | ABBVIE INC. | $1,582.80 | 01/09/2025 | Non-covered Recipient Entity PFLUGERVILLE DERMATOLOGY CLINICAL | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202437691 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503982 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 01/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503985 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503988 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503992 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504005 |
| Principal investigator 1 | Incyte Corporation | $5.38 | 01/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504009 |
| Principal investigator 1 | Incyte Corporation | $201.40 | 01/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504017 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 01/02/2025 | Non-covered Recipient Entity AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240504026 |